← The SEC Ephemeris: the whole map
Scienture Inc. losartan potassium
In the graph: all 2 documents (146 pages).
- Application
- NDA 218772
- Ticker
- SCNX
- Product
- losartan potassium
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- August 19, 2024
From FDA letters and SEC filings. Not investment or medical advice.